Abstract |
In the search for potent and selective human β3-adrenergic receptor (AR) agonists as potential drugs for use in treating obesity and non- insulin dependent ( type 2) diabetes, a series of N-phenyl-(2-aminothiazol-4-yl)acetamides with phenoxypropanolamine moiety were prepared and their biological activities against human β3-, β2-, and β1-ARs were evaluated. Among these compounds, N-phenyl-(2-phenylaminothiazol-4-yl)acetamide (4 g), N-phenyl-(2-benzylaminothiazol-4-yl)acetamide (4j), and N-phenyl-[2-(3-methoxyphenyl)aminothiazol-4-yl] acetamide (6g) derivatives showed potent agonistic activity against the β3-AR with functional selectivity over the β1- and β2-ARs. In addition, these compounds exhibited significant hypoglycemic activity in a rodent model of diabetes.
|
Authors | Tatsuya Maruyama, Kenichi Onda, Takayuki Suzuki, Masahiko Hayakawa, Takumi Takahashi, Tetsuo Matsui, Toshiyuki Takasu, Itsuro Nagase, Mitsuaki Ohta |
Journal | Chemical & pharmaceutical bulletin
(Chem Pharm Bull (Tokyo))
Vol. 60
Issue 5
Pg. 647-58
( 2012)
ISSN: 1347-5223 [Electronic] Japan |
PMID | 22689403
(Publication Type: Journal Article)
|
Chemical References |
- Acetamides
- Adrenergic beta-3 Receptor Agonists
- Hypoglycemic Agents
- Phenoxypropanolamines
- Receptors, Adrenergic, beta-1
- Receptors, Adrenergic, beta-2
- Receptors, Adrenergic, beta-3
|
Topics |
- Acetamides
(chemistry)
- Administration, Oral
- Adrenergic beta-3 Receptor Agonists
(chemical synthesis, chemistry, therapeutic use)
- Animals
- Diabetes Mellitus, Type 2
(drug therapy)
- Disease Models, Animal
- Drug Evaluation, Preclinical
- Humans
- Hypoglycemic Agents
(chemical synthesis, chemistry, therapeutic use)
- Male
- Mice
- Obesity
(drug therapy)
- Phenoxypropanolamines
(chemistry)
- Receptors, Adrenergic, beta-1
(chemistry, metabolism)
- Receptors, Adrenergic, beta-2
(chemistry, metabolism)
- Receptors, Adrenergic, beta-3
(chemistry, metabolism)
|